Certara, Inc. (NASDAQ:CERT - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Certara in a report issued on Wednesday, January 15th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $0.29 per share for the year, up from their previous estimate of $0.28. The consensus estimate for Certara's current full-year earnings is $0.28 per share.
Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the business posted $0.06 EPS.
Other equities analysts have also issued research reports about the stock. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a research report on Friday, September 27th. Barclays decreased their target price on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $15.92.
Check Out Our Latest Report on Certara
Certara Stock Performance
NASDAQ CERT traded down $0.10 during trading hours on Friday, hitting $11.66. The company had a trading volume of 912,516 shares, compared to its average volume of 989,011. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.88 billion, a P/E ratio of -58.30, a price-to-earnings-growth ratio of 4.55 and a beta of 1.52. Certara has a fifty-two week low of $9.41 and a fifty-two week high of $19.87. The business has a fifty day simple moving average of $10.90 and a 200-day simple moving average of $11.95.
Hedge Funds Weigh In On Certara
Several large investors have recently bought and sold shares of the stock. Wasatch Advisors LP lifted its stake in shares of Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock worth $105,577,000 after acquiring an additional 1,651,076 shares during the period. Geneva Capital Management LLC lifted its position in Certara by 0.7% in the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company's stock worth $64,525,000 after purchasing an additional 37,392 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company's stock worth $45,691,000 after purchasing an additional 1,128,006 shares during the period. State Street Corp boosted its stake in Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company's stock valued at $43,089,000 after purchasing an additional 122,411 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company's stock valued at $42,643,000 after purchasing an additional 273,095 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.
About Certara
(
Get Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Featured Articles
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.